Wells Fargo Maintains Overweight on Tectonic Therapeutic, Lowers Price Target to $93
Wells Fargo analyst Tiago Fauth maintains Tectonic Therapeutic (NASDAQ:TECX) with a Overweight and lowers the price target from $101 to $93.
Stocks · News reference
Tectonic Therapeutic Completes Enrollment For The APEX Trial, A 24-Week Phase 2 Clinical Trial Evaluating The Safety And Efficacy Of TX45 In Patients With Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction; APEX Phase 2 Trial Enrolled 191 Patients Across 14 Countries, With ~72% Of Patients In The Enriched Population Of CpcPH With A Pulmonary Vascular Resistance >3 WU At Baseline
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Tectonic Therapeutic Q2 EPS $(1.18) Beats $(1.37) Estimate
Tectonic Therapeutic (NASDAQ:TECX) reported quarterly losses of $(1.18) per share which beat the analyst consensus estimate of $(1.37) by 13.87 percent. This is a 10.28 percent decrease over losses of $(1.07) per share
8-K filing — Tectonic Therapeutic, Inc. (TECX)
Filed: 2026-06-10 AccNo: 0001193125-26-266040 Size: 173 KB Item 5.07: Submission of Matters to a Vote of Security Holders Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits